AOL Money & Finance

abbott labs posts

Feed

Turnaround expert targets laggard pharmaceuticals

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Goldman Sachs upgraded the banking sector last week, and this coming week we'll get a chance to see whether Goldman and other big banks reporting third quarter results will live up to the expectations of analysts surveyed by Thomson Reuters.

New York-based Goldman Sachs Group Inc. (NYSE: GS) looks set to be this week's earnings game winner. Analysts expect this dividend-paying company to report a third-quarter profit of $4.24 per share, which is 57.3% higher than in the same period of last year. Revenue for the period that ended in September is expected to be $11.0 billion. So far, the full-year forecast is for $17.74 per share on $44.6 billion.

Continue reading Week in preview: Goldman Sachs, JPMorgan, Google, IBM and more earnings

Vita Nelson: DRIP expert votes for Abbott (ABT)

In her The MoneyPaper, editor Vita Nelson looks to stocks offering dividend reinvestment plans. Here, she highlights Abbott Laboratories (NYSE: ABT) as a featured holding in her model portfolio.

"Abbott is a diversified, multinational, health care firm.The shares have not responded to the recent stock market rallies in part due to the defensive nature of health care stocks.

"Uncertainty regarding health care reform is also a factor in the static share price of recent months. ABT shares are now trading below 11 times 2010 earnings estimates, compared with about 15 for the S&P 500.

Continue reading Vita Nelson: DRIP expert votes for Abbott (ABT)

Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Charles Schwab and Abbott Labs top Q1 estimates

On Wednesday, Charles Schwab Corp. (NASDAQ: SCHW) reported that its lower first-quarter earnings easily topped analysts' estimates, and Abbott Laboratories (NYSE: ABT) said its higher first-quarter profit edged past Wall Street expectations. Shares of Schwab surged while those of Abbott Labs fell Wednesday.

San Francisco-based brokerage and investment manager Charles Schwab said it earned $218 million, or 19 cents per share, for the quarter, as compared to $305 million, or 26 cents per share, in the same period of the previous year. Total revenue fell 15% year over year to $1.11 billion.

Continue reading Charles Schwab and Abbott Labs top Q1 estimates

Abbott (ABT): An 'income machine'

"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.

"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

"The company employs more than 68,000 people and markets its products in more than 130 countries.

"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.

Continue reading Abbott (ABT): An 'income machine'

Turnaround time for drug stocks? 10 top picks

"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.

Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is his overview.

"In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies?

"Demand for their products was growing as the population aged. These companies had huge research
and development programs that seemed to keep cranking out new blockbuster drugs. And most of them had great balance sheets, with many paying handsome dividends.

"Much of this reasoning has been borne out in the intervening years. Many large drug manufacturers have rung up substantial revenue gains over the last decade. So what's happened to the big drug stocks? With few exceptions they have gone sideways or down – in some cases down a lot.

Continue reading Turnaround time for drug stocks? 10 top picks

Earnings highlights: Google, Intel, Coca-Cola, Pfizer, eBay, AMD and others

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Google, Intel, Coca-Cola, Pfizer, eBay, AMD and others

Abbott Labs swings to profit; WellPoint meets estimates

Abbott Laboratories (NYSE: ABT) announced that it swung to a profit in the fourth quarter from year-earlier results that were reduced by charges for acquisition costs. Abbott's drugs Humira, Depakote, TriCor, and Kaletra all posted double-digit sales gains.

For the quarter ending December 31, Abbott earned $1.2 billion, or 77 cents per share, compared with a loss of $476.2 million, or 31 cents per share, in the same period a year ago. Revenue rose to $7.22 billion from $6.22 billion, exceeding the $6.97 billion estimated by analysts polled by Thomson Financial.

Adjusted earnings, excluding certain items, rose to 93 cents per share, a penny better than analysts' consensus estimate. For the full year, Abbott earned $3.6 billion, or $2.31 a share, compared with $1.72 billion, or $1.12 a share, in 2006. Revenue increased 15% to $25.9 billion from $22.5 billion.

Shares were down about 2% to 56.20 by midday on Wednesday.

For more news on Abbott Labs, see BloggingStocks' Abbott coverage.

Continue reading Abbott Labs swings to profit; WellPoint meets estimates

Best Stocks for 2008: Abbott Laboratories (ABT)

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"My favorite conservative idea for 2008, Abbott Laboratories (NYSE: ABT), is a leading player in several growing health care markets, offering a wide range of prescription pharmaceuticals, nutritional and diagnostic products, and medical devices," says Jim Stack, money manager and editor of InvesTech Market Analyst.

"The company has a long history of stable sales and earnings growth fostered by its strong research and development program, acquisitions and global expansion. As a defensive health care play, we particularly like the diversification this company provides.

"It derives nearly 30% of profits from overseas markets, while pharmaceuticals account for 44% of sales, hospital products 20%, nutritional products 18% and diagnostics 15%.

"Currently, Abbott is enjoying double-digit sales growth in three of these four major divisions, and we expect this strength to continue at least through 2008. The company is a bright spot in the drug industry, which has been plagued in recent years by patent expirations and meager product pipelines.

Continue reading Best Stocks for 2008: Abbott Laboratories (ABT)

Abbott, GE abandon sale of diagnostics unit

Abbott Laboratories (NYSE: ABT) will not sell its primary in-vitro and point-of-care diagnostics businesses to General Electric (NYSE: GE) as planned, both companies say, due to a disagreement on the final terms of the $8.13 billion proposal.

Despite being approved by regulators in the U.S. and Europe, GE says that it was in both of their best interests to terminate it. The move would have given GE its first entry into the laboratory testing space.

The Wall Street Journal believes that the breakup may have been related to the continued regulatory problems at Abbott's Irving, TX, manufacturing facility. The unit has been problematic for Abbott, with $100 million in fines back in 1999. The FDA called Abbott's devices "adulterated" and "misbranded," which could have made GE nervous about taking on regulatory issues.

Some analysts say the deal's failure is a good thing because they think GE was overpaying. "Health care," says JP Morgan's Stephen Tusa in the Journal, "is still a place that we want to see them invest."

Abbott said the decision to cancel the contract would have no impact on their previously issued second-quarter or full-year guidance, excluding specified items. JP Morgan told investors this morning to buy shares of Abbott on the weakness from the news, saying that while the break-up is a setback, the company's broader plan is still intact.

Summer Street Research believes the lack of a deal between GE and Abbott could fuel speculation that one of them may now be interested in pursuing Ventana Medical Systems (NASDAQ: VMSI), the medical equipment supplier that recently rejected a $3 billion hostile offer from Roche Holding Ag (OTC: RHHBY).

GE to buy part of Abbott Labs for over $8 billion

One of the world's largest companies, General Electric Company (NYSE:GE), will be acquiring some of the medical diagnostics business of Abbott Laboratories for $8.13 billion in cash, according to both companies as as late last week.

What does this move give GE? It will deeply increase the importance GE has been placing recently on its health care business, which right now is pegged at a $16 billion figure for GE annually.

GE CEO Jeff Immelt said the acquisition is "consistent with GE's strategy to invest in high-technology global infrastructure businesses that deliver strong top-line growth, earnings expansion and expanded margins." Easy enough said.

Abbott's partial sale to GE will net the company about $6 billion in after-tax cash according to the company, which will use the money primarily to pay down debt and supplement share repurchases.

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 25, 2009: 07:48 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance